The DCTI consortium was founded by two university hospitals, LUMC and UMCG, which have expertise in transplantation and beta-cell research, the University Twente with a focus on tissue engineering, several biotech companies (Galapagos, Xpand Biotechnology, and Polyganics) and the Dutch Diabetes Research Foundation. They have united to improve beta-cell therapy in diabetes and widen its applicability.

The DCTI consortium was financially supported by the Dutch Diabetes Research Foundation and was one of the consortia supported by LSH-FES.

Much of the knowledge generated within DCTI will be used in RegMed XB. For more information on RegMed XB see:

Overview DCTI